ViiV Healthcare K.K. (President: Hirohisa Iriyama; Head Office: Shibuya-ku, Tokyo; hereinafter referred to as “ViiV Healthcare”) announces that Triumeq® Combination Tablets (Combination tablets containing dolutegravir sodium, abacavir sulfate and lamivudine; hereinafter referred to as Triumeq®) which was approved by the Ministry of Health, Labour and Welfare for the treatment of HIV infection on March 16, 2015, was launched on April 10, 2015 following the NHI price listing on March 25, 2015. As with existing HIV medicines, Triumeq® is exempt from 14 days prescription rule of new medicines.

ViiV Healthcare and Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereinafter referred to as “Shionogi”), in accordance with the Co-promotion Agreement in Japan concluded for this product, have been carrying out from date of approval (March 16, 2015) to jointly provide medical information on Triumeq® to medical institutions. The distribution and sales operations will be conducted by GlaxoSmithKline K.K. (Head Office: Tokyo; President: Philippe Fauchet), in the same way as for existing products of ViiV Healthcare in Japan.

Triumeq® is the company’s first fixed-dose combination tablet for a once-daily single-pill regimen that combines dolutegravir, an integrase inhibitor, with the nucleoside reverse transcriptase inhibitors abacavir and lamivudine. Triumeq® was approved for the indication of HIV infection in August 2014 in the US and in September 2014 in Europe, and is being sold under the product name of Triumeq®.

Dolutegravir, which is one of the drug’s three active ingredients, was approved as Tivicay® Tablets 50 mg on March 24, 2014 and was launched on April 17 of the same year, and ViiV and Shionogi also have been conducting co-promotion on this product.

ViiV Healthcare and Shionogi aim to contribute to improving the treatment of HIV infection for all the people who are living with HIV in Japan and maximize the value of this drug by providing proper information to medical professionals. Furthermore, the two companies will promote the proper use of this drug and distribute this new treatment option to patients in order to address unmet medical
needs that cannot be met with the existing drugs of this therapeutic area.

### About Triumeq®

<table>
<thead>
<tr>
<th>Product name</th>
<th>Triumeq®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonproprietary name</td>
<td>Dolutegravir, abacavir and lamivudine</td>
</tr>
<tr>
<td>Approval date</td>
<td>March 16, 2015</td>
</tr>
<tr>
<td>Launch date</td>
<td>April 10, 2015</td>
</tr>
<tr>
<td>NHI Price</td>
<td>1Tab : 7,000.30YEN</td>
</tr>
<tr>
<td>Indication</td>
<td>HIV infectious disease</td>
</tr>
</tbody>
</table>

**Dosage and administration**
The usual oral dose of Triumeq for adult patients is one tablet (containing 50 mg of dolutegravir, 600 mg of abacavir, and 300 mg of lamivudine) once daily with or without food.

**Marketing authorization holder**
ViiV Healthcare K.K.

**Distributor**
GlaxoSmithKline K.K.

**Co-promoter**
Shionogi & Co., Ltd.

### About Human Immunodeficiency Virus (HIV) infection

Human Immunodeficiency Virus (HIV) infects human immune cells called CD4 T lymphocytes, a type of white blood cells that play a central role in the human immune system. CD4 T lymphocytes are destroyed gradually due to HIV infection, causing the patients’ immune functions to decline. Eventually, patients exhibit various types of opportunistic infections and malignant tumours as a complication, a condition referred to as Acquired Immune Deficiency Syndrome (AIDS). According to a report by the MHLW’s Committee on AIDS Trends, a total of 1,106 people were reportedly diagnosed as HIV infection (without AIDS) in 2013, and 484 patients suffered AIDS at the time of HIV diagnosis. The total number of newly reported cases in 2013, therefore, came to be 1,590 patients. The cumulative number of cases that have been reported up to 2013 (excluding cases of infections caused by coagulation factor preparations) is approximately 23,000.

### About ViiV Healthcare

ViiV Healthcare LLC is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined as a shareholder in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit [www.viivhealthcare.com](http://www.viivhealthcare.com).

ViiV Healthcare K.K. is the Japanese subsidiary of ViiV Healthcare LLC in the UK. For more
information on the company, please visit http://glaxosmithkline.co.jp/viiv/.

About Shionogi & Co., Ltd.
Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients based on its corporate philosophy of “supply the best possible medicine to protect the health and wellbeing of the patients we serve,” Shionogi’s research and development currently targets two therapeutic areas: infectious diseases, and pain/CNS disorders. In addition, Shionogi is engaged in new research areas such as obesity/geriatric metabolic disease and oncology/immunology. Contributing to the health and QOL of patients around the world through development in these therapeutic areas is Shionogi’s primary goal. For more details, please visit www.shionogi.co.jp.

<Reference>

Media contacts:
ViiV Healthcare K.K. Mitsuhiro Kitamura TEL: +81-3-5786-6043
GlaxoSmithKline K.K. Yuko Fuke TEL: +81-3-5786-5041

Shionogi & Co., Ltd., Corporate Communications
Osaka TEL: +81-6-6209-7885 FAX: +81-6-6229-9596
Tokyo TEL: +81-3-3406-8164 FAX: +81-3-3406-8099